HIV-1 integrase inhibitors with modifications that affect their potencies against drug resistant integrase mutants
More about Open Access at the CrickAuthors list
Steven J Smith Xue Zhi Zhao Dario Oliveira Passos Val Pye Peter Cherepanov Dmitry Lyumkis Terrence R Jr Burke Stephen H HughesAbstract
Integrase strand transfer inhibitors (INSTIs) block the integration step of the retroviral lifecycle and are first-line drugs used for the treatment of HIV-1/AIDS. INSTIs have a polycyclic core with heteroatom triads, chelate the metal ions at the active site, and have a halobenzyl group that interacts with viral DNA attached to the core by a flexible linker. The most broadly effective INSTIs inhibit both wild-type (WT) integrase (IN) and a variety of well-known mutants. However, because there are mutations that reduce the potency of all of the available INSTIs, new and better compounds are needed. Models based on recent structures of HIV-1 and red-capped mangabey SIV INs suggest modifications in the INSTI structures that could enhance interactions with the 3'-terminal adenosine of the viral DNA, which could improve performance against INSTI resistant mutants. We designed and tested a series of INSTIs having modifications to their naphthyridine scaffold. One of the new compounds retained good potency against an expanded panel of HIV-1 IN mutants that we tested. Our results suggest the possibility of designing inhibitors that combine the best features of the existing compounds, which could provide additional efficacy against known HIV-1 IN mutants.
Journal details
Journal ACS Infectious Diseases
Volume 7
Issue number 6
Pages 1469-1482
Available online
Publication date
Full text links
Publisher website (DOI) 10.1021/acsinfecdis.0c00819
Figshare View on figshare
Europe PubMed Central 33686850
Pubmed 33686850
Keywords
Related topics
Type of publication